Discover and download resources

files selected

Clear

Patient Discussion Guide

This guide includes helpful tips for discussing VYEPTI migraine prevention with your patients, including what they may expect from their IV treatment.

VYEPTI Infusion Checklist

Use this checklist to keep track of the complete VYEPTI dosing and administration process.

VYEPTI Dosing and Administration Guide

Step-by-step instructions for administering VYEPTI.

VYEPTI Antibody Science Review

Explore this brief overview of CGRP in migraine pathophysiology and the science behind therapeutic antibodies, including the purposeful design of VYEPTI.

Eptinezumab-jjmr—The Purposeful Design

Discover the intentional design features of eptinezumab-jjmr.

VYEPTI Dosing and Administration Video

Step-by-step instructions for the preparation and administration of VYEPTI.

Introducing VYEPTI Video

Explore the clinical benefits and safety profile of VYEPTI.

Electra Patient Testimonial Video

Watch Electra discuss her experience with chronic migraine and VYEPTI.

VYEPTI: From Data to Patient Experience Video

Watch Dr Dawn C Buse, PhD, and Dr Andrew C Charles, MD, as they speak with Electra, a real migraine patient treated with VYEPTI. Learn about efficacy and safety data for VYEPTI and patient considerations when selecting treatment.

PROMISE-1 VYEPTI resource thumbnail

PROMISE-1 Study

Explore the pivotal trial results for eptinezumab-jjmr in episodic migraine.

PROMISE-2 VYEPTI resource thumbnail

PROMISE-2 Study

Explore the pivotal trial results for eptinezumab-jjmr in chronic migraine.

VYEPTI patient support resources thumbnail

Patient Support Resources

See a variety of resources that can help support your VYEPTI patients.

Want updates when more resources become available?

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.